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PURPOSE. Pharmacological activation of ocular surface cystic fibrosis transmembrane
conductance regulator (CFTR) chloride channels is a potential pro-secretory approach to
treat dry eye disorders. We previously reported the discovery of aminophenyl-1,3,5-triazines,
one of which, N-methyl-N-phenyl-6-(2,2,3,3-tetrafluoropropoxy)-1,3,5-triazine-2,4-diamine
(herein called CFTRact-K267), fully activated human wildtype CFTR with EC50 ~ 30 nM and
increased tear volume for 8 hours in mice. Here, functional and pharmacological studies of
CFTRact-K267 were done in adult New Zealand white rabbits.
METHODS. CFTR chloride conductance was measured in vivo by ocular surface potential
differences and in ex vivo conjunctiva by short-circuit current. Tear volume was measured by
the Schirmer tear test II and CFTRact-K267 pharmacokinetics and tissue distribution by liquid
chromatography/mass spectrometry. Toxicity profile was studied for 28 days with twice-daily
topical administration.
RESULTS. Electrophysiological measurements in vivo and in ex vivo conjunctiva demonstrated
CFTR activation by CFTRact-K267. A single topical dose of 3 nmol CFTRact-K267 increased tear
production by >5 mm for 9 hours by the Schirmer tear test, with predicted therapeutic
concentrations maintained in tear fluid. No tachyphylaxis was seen following 28-day twice-
daily administration, and changes were not observed in corneal surface integrity or thickness,
intraocular pressure, or ocular histology. At day 28, CFTRact-K267 was concentrated in the
cornea and conjunctiva and was not detectable in blood or peripheral organs.
CONCLUSIONS. These studies support the development of CFTRact-K267 as a pro-secretory
therapy for dry eye disorders.
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Dry eye disorders constitute a significant health care burden,particularly in an aging population. Current treatment
options include artificial tears, punctal plugs, and the topical
anti-inflammatory drugs cyclosporine and lifitegrast.1–3 There is
compelling rationale for development of pro-secretory therapy
in dry eye, as increasing the volume of tear fluid bathing the
ocular surface is predicted to reduce tear fluid hyperosmolality,
which drives the downstream inflammatory response and
consequent symptoms.
An attractive target for pro-secretory therapy of dry eye is
cystic fibrosis transmembrane conductance regulator (CFTR), a
cAMP-regulated chloride channel that is expressed in corneal
and conjunctival epithelial cells as well as in various secretory
epithelia outside of the eye.4–11 Although CFTR at the ocular
surface is largely inactive under normal conditions, as it is in the
intestine, once activated it can drive fluid secretion at the
ocular surface, as it does in the intestine in secretory diarrheas
such as cholera.12,13 Few ocular surface abnormalities have
been reported in cystic fibrosis humans with loss-of-function
mutations in CFTR,14,15 providing evidence for minimal basal
CFTR activity at the ocular surface. As CFTR activation drives
fluid secretion by epithelial cells lining the ocular surface,
augmentation of tear fluid does not require functional lacrimal
or Meibomian glands.
We recently identified by high-throughput screening an
aminophenyl-1,3,5-triazine class of small molecule activators of
wildtype CFTR. A compound from the screen, CFTRact-K089
(Fig. 1), fully activated CFTR in cell cultures with EC50 ~250
nM and, when delivered topically to mice, doubled tear volume
for 4 hours.16 In lacrimal gland ablation models in mice,
CFTRact-K089 administered three times daily normalized tear
volume, prevented corneal epithelial disruption, and even
reversed pathology when administered after development of
dry eye. In a recent medicinal chemistry study, the CFTRact-
K089 analog N-methyl-N-phenyl-6-(2,2,3,3-tetrafluoropropoxy)-
1,3,5-triazine-2,4-diamine (herein called CFTRact-K267) fully
activated CFTR with EC50 ~ 30 nM and produced a sustained
increase in tear volume in mice for 8 hours following 25 pmol
topical administration.17 CFTRact-K267 was without effect in
CFTR-deficient mice and was rapidly metabolized by the liver, a
desirable characteristic for minimizing systemic exposure.
Here, to advance CFTRact-K267 in its preclinical develop-
ment, the activity and pharmacology of CFTRact-K267 were
studied in rabbit as a model of human ocular surface
physiology.
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MATERIALS AND METHODS
Rabbits
A total of 24 adult female New Zealand white rabbits (Western
Oregon Rabbit Co., Philomath, OR, USA) weighing 2 to 3 kg
were used for this study. Rabbits were acclimated for 3 days
prior to experiments and raised under standard laboratory
conditions. Rabbit protocols were approved by the University
of California, San Francisco Institutional Animal Care and Use
Committee and conducted in accordance with the ARVO
Statement for the Use of Animals in Ophthalmic and Vision
Research.
Chemicals and Formulation
CFTRact-K267 was synthesized by stepwise substitution reac-
tions of cyanuric chloride with methylamine, 2,2,3,3-tetra-
fluoropropanol, and aniline under basic conditions, as
described,17 and purified to >95% by flash chromatography
(1:2 ethyl acetate:hexane). CFTRact-K267 was prepared as a 10
mM dimethyl sulfoxide (DMSO) stock solution. The ophthal-
mic formulation contained 0.22-lm filtered Ringer’s solution
containing 0.3% carboxymethylcellulose (CMC, high viscosity;
VWR, Radnor, PA, USA), 0.015% benzalkonium chloride
preservative, and 1% DMSO at pH 7.40. For some studies a
higher concentration of CMC (0.665%) was used to increase
viscosity.
Ocular Surface Potential Difference Measurements
Open-circuit transepithelial potential difference (PD, in mV) at
the ocular surface was measured continuously in anesthetized
rabbits using a procedure modified from that established in
mice.8 Rabbits were intubated and anesthetized with isoflur-
ane, and respiratory rate, blood pressure, and body tempera-
ture were monitored. For PD recording, solutions (see below)
were serially perfused at 10 mL/min through PE-90 plastic
tubing using a gravity multireservoir pinch-valve system (ALA
Scientific, Westbury, NY, USA) and a variable-flow peristaltic
pump (medium flow model; Thermo Fisher Scientific, Fair
Lawn, NJ, USA). A perfusion catheter was fixed onto an
adjustable stereotaxic frame with the tip immersed in solution
contacting the ocular surface, as diagrammed in Figure 2A.
Excess fluid was aspirated by continuous suction (low-
powered wall vacuum) using 1/8-inch tubing (inner diameter
3/32 inch) placed 3 mm from the lateral canthus to maintain
near-constant perfusate volume in contact with cornea, bulbar
conjunctiva, and palpebral conjunctiva without fluid runoff.
The measuring electrode contacted the perfusion catheter and
was connected to a high-impedance voltmeter (IsoMilivolt
Meter; World Precision Instruments, Sarasota, FL, USA). The
reference electrode was grounded using a winged, 25-gauge
needle filled with normal saline inserted subcutaneously in the
FIGURE 1. Chemical structures of CFTR activators CFTRact-K089 and
CFTRact-K267.
FIGURE 2. Electrophysiological analysis of CFTR activation by CFTRact-K267 at the rabbit ocular surface. (A) Schematic (top) and photograph
(bottom) of ocular surface potential difference (PD) recording method. The perfusion catheter coupled to the measuring electrode was oriented
perpendicular to the ocular surface near the medial canthus. The eyelids create a natural reservoir for corneal and conjunctival exposure, with
vacuum aspiration maintaining a stable perfusate volume. (B) Left: Representative ocular surface PD recording in response to sequential solution
exchanges. Right: Summary of PD changes (D PD) in response to indicated maneuvers (mean 6 SEM; n¼ 16 eyes). (C) Left: Representative short-
circuit current (Isc) measurement in freshly isolated rabbit forniceal and palpebral conjunctiva in response to compound additions. Right: Summary
of changes in Isc (D Isc) in response to compound additions (mean 6 SEM; n¼ 3).
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abdomen. The measuring and reference electrodes consisted of
Ag/AgCl with 3 M KCl agar bridges.
Solutions consisted of the following: (1) normal Cl solution
(mM): 99 NaCl, 24 KCl, 32 NaHCO3, 1.0 NaH2PO4, 0.6 MgCl2,
0.8 CaCl2; (2) normal Cl
 solution with amiloride (100 lM); (3)
low Cl solution with amiloride (NaCl replaced by Na
gluconate and KCl by K gluconate); (4) low Cl þ amiloride
þCFTRact-K267 (1 lM); (5) low Clþ amilorideþCFTRact-K267
(10 lM); (6) low Cl þ amiloride þ CFTRact-K267 (10 lM) þ
forskolin (20 lM); (7) low Cl þ amiloride þ forskolin þ
CFTRact-K267 (10 lM) þ CFTRinh-172 (10 lM). The solutions
were isosmolar to rabbit tear film (302 mOsm) with a pH of
7.4. All solutions contained 10 lM indomethacin to prevent
CFTR activation by prostaglandins. As has been done in many
tissue electrophysiology studies, indomethacin was included to
minimize stress- or trauma-induced prostaglandin production.
Indomethacin was found to improve reproducibility in our
previous mouse ocular PD studies.8
Short-Circuit Current Measurements
Short-circuit current was measured in freshly isolated rabbit
conjunctiva, as described16 with modification. Rabbits were
euthanized by injection of 150 mg/kg euthasol into the
marginal ear vein. The entire eyeball with eyelids intact was
removed from the orbit to preserve conjunctival epithelial
integrity. Within 10 minutes, a sheet of forniceal and palpebral
conjunctiva was dissected, mounted onto a P2304 tissue slider
(Physiologic Instruments, San Diego, CA, USA), and placed into
the Ussing chamber. The apical and basolateral chambers
contained (in mM): 120 NaCl, 3 KCl, 1 CaCl2, 1 MgCl2, 10
glucose, 25 NaHCO3, and 5 HEPES, pH 7.4. Solutions were
bubbled with 95% O2/5% CO2 and maintained at 378C.
Hemichambers were connected to a DVC-1000 voltage clamp
(World Precision Instruments Inc., Sarasota, FL, USA) via Ag/
AgCl electrodes and 3 M KCl agar bridges.
Schirmer Tear Test II
Tear production was measured using the anesthetized Schirm-
er Tear Test (STT, Eagle Vision, Memphis, TN, USA). To
minimize reflex tearing, one drop of 0.5% proparacaine
hydrochloride (Akorn, Lake Forest, IL, USA) was placed onto
the corneal surface and excess fluid was absorbed at the medial
canthus using eye spear sponges (Fine Science Tools, Foster
City, CA, USA). After 5 minutes, the notched strip was inserted
into the lower lateral conjunctival fornix, maintaining contact
with the lateral cornea. The wetted length (mm) of the strip
indicated by blue dye appearance was read after 5 minutes.
Pharmacodynamics
Serial STT measurements were done before and at 1, 3, 6, 9, 12,
and 24 hours following application of a single 30-lL drop of
CFTRact-K267 formulation (or vehicle alone) into the conjunc-
tival sac. Both eyes received the same treatment to control for
potential contralateral effects of a given treatment.
Pharmacokinetics and Tissue Distribution
CFTRact-K267 was quantified by liquid chromatography/mass
spectroscopy (LC/MS) at 15 minutes, 1 hour, 2 hours, 6 hours,
and 24 hours after a single, 3-nmol topical dose. To recover
CFTRact-K267 at indicated times, three eye washes of 30 lL
sterile PBS were done with solution recovered from the lateral
and medial canthi after manual eyelid blinking using 50-lL
glass capillary tubes. Pooled washes were diluted in three
volumes of ethyl acetate, centrifuged at 18,500g for 15 min,
and the collected supernatant was analyzed by LC/MS (Waters
2695 HPLC with Micromass ZQ).16 LC was done on an Xterra
MS C18 column (2.1 mm3 100 mm, 3.5 lm) with 0.2 mL/min
water/acetonitrile containing 0.1% formic acid, 12-minute
linear gradient, and 5% to 95% acetonitrile.
In chronic treatment studies, CFTRact-K267 (3 nmol, or
formulation control) was given twice daily (8 AM and 4 PM) for
28 days. Two mL of blood was collected from the marginal ear
vein in EDTA tubes. Rabbits were then euthanized using 150
mg/kg euthasol, and ocular tissues, blood, and peripheral
organs were collected. Using a surgical microscope, 150 lL of
aqueous humor was collected through the peripheral cornea
using a 25-gauge needle, and 300 lL of vitreous fluid was
aspirated through the pars plana with a 23-gauge needle.
Following transcardial perfusion with heparinized PBS, the
eyes were enucleated with lids intact, and the cornea, iris/
ciliary body, lens, bulbar, forniceal and palpebral conjunctiva,
and retina of both eyes were dissected, weighed, homogenized
in a 1:4 mixture of water:ethyl acetate (10 mL/1 g tissue), and
centrifuged (1000g for 15 minutes). Plasma, aqueous, and
vitreous samples were each mixed with 3 volumes of ethyl
acetate and centrifuged for 15 minutes at 18,500g, and the
supernatant was evaporated and redissolved in HPLC eluent
(100 lL of 1:3 water:acetonitrile containing 0.1% formic acid)
for LC/MS analysis. Also, the brain, kidney, heart, and liver were
removed, weighed, mixed in a 1:4 mixture of water:ethyl
acetate (10 mL/1g tissue), and homogenized. The homogenized
samples were vortexed and centrifuged (1000g for 15
minutes), and the ethyl acetate-containing supernatant was
evaporated and then redissolved in HPLC eluent for LC/MS
analysis. The lower limit of detection for CFTRact-K267 was
~0.2 pg/mg of homogenized tissue or biological fluid, which
was defined as giving a signal-to-noise ratio >3.
Clinical Examination
In chronic treatment studies, eyes were treated twice daily for
28 days as described previously. STT, intraocular pressure
(IOP), and central corneal thickness were measured on days 0,
7, 14, 21, and 28. Slit lamp examinations were performed on
days 0, 14, and 28 by a board-certified ophthalmologist blinded
to treatment status. STT was done 1 hour after the first
treatment of the day (9 AM). IOP was measured with a Tonolab
rebound tonometer (Colonial Medical Supply, Windham, NH,
USA). Central corneal thickness was measured using the
Corneo-Gage Plus 2 pachymeter (Sonogage Inc., Cleveland,
OH, USA). For slit lamp examination, Lissamine green strips
(GreenGlo, HUB Pharmaceuticals LLC, Rancho Cucamonga,
CA, USA) were wetted with 25 lL lubricant eye drops and then
applied gently into the inferior fornix. One minute later,
photographs of the eye were taken with a digital camera and
staining was evaluated according to a 12-point scale as
described18: each corneal quadrant was scored in a blinded
fashion on a 3-point scale: grade 0, no staining; grade 1,
sporadic staining (involving <25% of the total surface); grade 2,
diffuse punctate staining (25%–75%); and grade 3, coalesced
punctate staining (‡75%). The total grade is reported as the
sum of scores from all four quadrants, ranging from 0 to 12.
Conjunctival congestion, chemosis, discharge, corneal haze or
neovascularization, anterior chamber cellular reaction or flare,
iris neovascularization, lens opacification, or loss of red reflex
were each rated using a modified four-point McDonald-
Shadduck scale, where zero is normal.
Histology
A subset of chronically treated eyes were enucleated with
eyelids intact after transcardial perfusion with PBS followed by
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4% paraformaldehyde and left overnight in 48C in 30% sucrose.
Eyes were embedded in optimal cutting temperature com-
pound (OCT) and sectioned through central cornea, posterior
pole, and superior and inferior fornices/eyelids. Cryosections
(8 lm thickness) were stained with hematoxylin and eosin
using a standard protocol.
Statistics
Data are presented as mean 6 SEM. Statistical analyses were
performed using GraphPad Prism software (GraphPad, San
Diego, CA, USA). Serial tear volume measurements, IOP, and
corneal thickness were analyzed by 2-way ANOVA with
Dunnett post hoc analysis.
RESULTS
CFTRact-K267 Activates CFTR Chloride
Conductance at the Rabbit Ocular Surface
CFTRact-K267 activity at the ocular surface in rabbits in vivo
was measured using an open-circuit PD method, as developed
originally in mice. The method involves perfusion of the ocular
surface with a series of solutions during continuous measure-
ment of PD using a high-impedance voltmeter, as diagrammed
in Figure 2A. The average absolute PD measured initially was
14 6 1 mV (mean 6 SEM, n ¼ 16 eyes). The representative
PD curve in Figure 2B (left) shows an initial depolarization
following addition of the ENaC inhibitor amiloride, with
hyperpolarizations following perfusion with low Cl solutions
without and then with CFTRact-K267, and then with a high
concentration of the cAMP agonist forskolin to maximally
activate CFTR. The CFTR inhibitor CFTRinh-172 was present in
the final perfusion solution. CFTRact-K267 produced a substan-
tial depolarization that was minimally further increased by
forskolin, with the depolarizations largely reversed by CFTRinh-
172. Averaged changes in PD from measurements done on 16
eyes are summarized in Figure 2B (right). These results confirm
activation of CFTR at the rabbit ocular surface by CFTRact-
K267. However, ocular-surface PD data should be considered
semiquantitative because of nonlinearity in PD values with
CFTR function and because of uncertainties in the extent of
perfusate fluid contact with whole ocular surface and of
compound accumulation in ocular surface cells.
In separate electrophysiological studies, CFTR activation
was measured in freshly isolated conjunctiva ex vivo by short-
circuit current analysis. The representative curve in Figure 2C
(left) shows a small increase in current in response to addition
of a low concentration of forskolin (25 nM), which was further
increased by 1 and then 10 lM CFTRact-K267. Maximal CFTR
activation was produced by a high concentration of forskolin.
The increases in short-circuit current were inhibited by
CFTRinh-172. Amiloride (10 lM) had no effect on short-circuit
current (not shown). Averaged changes in short-circuit current
are summarized in Figure 2C (right). These ex vivo results
confirm CFTRact-K267 activation of CFTR in conjunctival
epithelium, with the data at 1 versus 10 lM CFTRact-K267
indicating an apparent EC50 < 1 lM.
CFTRact-K267 Pharmacodynamics
CFTRact-K267 was tested for its efficacy in augmenting tear
fluid production in rabbits. Prior work identified a formulation
(0.325% CMC in Ringer’s solution containing 0.015% benzal-
konium chloride and 1% DMSO) that stably solubilized CFTRact-
K267 and was effective when delivered topically to mice.17 A
single application of 3 nmol CFTRact-K267 (10 lL of a 100 lM
solution) increased tear volume by ~60% for at least 9 hours
when compared with vehicle (Fig. 3A). Dose-dependence
studies showed similar activity of 6 nmol CFTRact-K267, but
reduced duration of activity with 1.5 nmol CFTRact-K267 and
no significant increase in tear production with 0.75 nmol
CFTRact-K267 (Fig. 3B). When 3 nmol of CFTRact-K267 was
delivered in a more viscous formulation containing 0.625%
(instead of 0.3%) CMC, to potentially increase CFTRact-K267
ocular surface residence time, compound efficacy was
unchanged (Fig. 3C).
CFTRact-K267 Pharmacokinetics
Pharmacokinetics in tear fluid was measured by LC/MS
analysis of material recovered in three eye washes done at
specified times following a single topical dose of 3 nmol
CFTRact-K267. Figure 4A shows original LC/MS data and a
standard curve from which the amount of recovered CFTRact-
K267 was deduced. Figure 4B shows an approximate
exponential decline in CFTRact-K267 recovered from tear
fluid (closed circles, left axis). Corresponding compound
concentrations in tear fluid (open circles, right ordinate)
were estimated using tear volumes deduced from STT
measurements in Figure 2A. These results support the
conclusion that CFTRact-K267 remains at predicted therapeu-
tic concentrations in tear fluid for at least several hours
following administration of a 3-nmol dose.
Chronic Administration Studies
Repeated topical delivery of CFTRact-K267 (3 nmol, twice daily
for 28 days) augmented tear volume in a sustained fashion
without tachyphylaxis (Fig. 5A). No significant differences
were found comparing vehicle and CFTRact-K267-treated eyes
on IOP (Fig. 5B) or central corneal thickness (Fig. 5C). No
apparent acute ocular irritation was observed following topical
administrations, as evidenced by a lack of excessive blinking or
altered behavior. Slit-lamp evaluation showed no evidence of
conjunctival hyperemia, anterior chamber inflammation, or
lens opacification. Lissamine green staining showed no injury
to the ocular surface in vehicle-treated and CFTRact-K267-
treated eyes (Fig. 5D). Histology showed no pathological
changes in the cornea or conjunctiva at day 28 (Fig. 5E) or in
the lens, ciliary body, or retina (not shown).
Following the chronic treatment, CFTRact-K267 was below
the limit of detection by LC/MS in the blood, heart, brain, liver,
and kidney (Figs. 6A, 6B), indicating minimal systemic
exposure, as expected, given the rapid predicted hepatic
metabolism of CFTRact-K267 deduced from in vitro microsomal
stability measurements.17 In ocular tissues, the LC/MS analysis
showed CFTRact-K267 in cornea > conjunctiva >> retina, with
levels near or below the limit of detection in the aqueous and
vitreous fluid, lens, and iris/ciliary body. The low but
measurable level in retina, equivalent to <10 nM CFTRact-
K267, may result from trans-scleral transport because CFTRact-
K267 was not detected in the vitreous fluid.
DISCUSSION
The functional data showed rapid and prolonged activation of
CFTR chloride channels at the rabbit ocular surface following
exposure to CFTRact-K267. A single topical dose of 3 nmol
CFTRact-K267 produced a substantial and sustained increase in
tear secretion for at least 9 hours, which, if translated to human
dry eye, could have therapeutic efficacy with once- or twice-
daily dosing. The sustained augmentation in tear production
over 9 hours, averaging 5.3 mm by STT, corresponds to a 2.7 lL
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increase in tear fluid volume using the reported relationship
between STT wetting and volume.19,20 This study in rabbits
builds on our prior studies in mice,16,17 as rabbits are suitable
for detailed pharmacokinetic, tissue distribution, and pharma-
codynamic measurements as well as long-term toxicity studies
with noninvasive serial assessments of corneal health and
intraocular pressure. Also, rabbit eyes are considered better
surrogates for human eyes than are rodent eyes.
FIGURE 3. CFTRact-K267 increases tear fluid at the rabbit ocular surface as measured by Schirmer’s test. (A) Tear volume (mm, by Schirmer’s test)
measured just before and at the indicated times after single-dose topical application of 3 nmol CFTRact-K267 or formulation (containing 0.3% CMC)
control (mean 6 SEM; 8 eyes per condition). (B) Dose dependence with study done as in A, comparing 0.75, 1.5, and 6.0 nmol CFTRact-K267 (4
eyes per condition). (C) Effect of formulation viscosity, with study done as in A, for formulation containing 0.665% CMC instead of 0.3% CMC (4 eyes
per condition). *P < 0.05, **P < 0.01, ANOVA, comparing CFTRact-K267 versus vehicle-treated eyes.
FIGURE 4. CFTRact-K267 concentration in rabbit tear fluid following instillation of a single 3-nmol dose. (A) Standard LC/MS curve of aqueous
solutions containing specified concentrations of CFTRact-K267. (B) Recovered CFTRact-K267 (in pmol, closed circles, left ordinate) and deduced
concentration (in nM, open circles, right ordinate) in tear fluid. Each point is the average of measurements done on 2 eyes for each time point.
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Prior studies showed CFTR activation by CFTRact-K267 with
nanomolar potency and without detectable elevation of total
cellular cAMP.17 The absence of CFTRact-K267 effect in CFTR-
deficient mice supported CFTR-dependent action at the ocular
surface. Pharmacodynamic and pharmacokinetic studies here in
rabbits showed sustained elevation in tear aqueous production
with predicted therapeutic concentrations of CFTRact-K267 in
tear fluid. Chronic administration studies with twice-daily dosing
for 28 days revealed CFTRact-K267 accumulation in ocular tissue,
mainly in the cornea> conjunctiva>> retina, with levels below
FIGURE 5. Ocular toxicity studies in a chronic CFTRact-K267 administration model. Rabbits were treated with 3 nmol CFTRact-K267 (or vehicle
control) twice daily for 28 days. STT (A), IOP (B), and central corneal thickness (C) before and weekly following initiation of CFTRact-K267
administration (mean 6 SEM, 8 eyes). **P < 0.01, ANOVA, comparing CFTRact-K267 versus vehicle-treated eyes. (D) Left: Representative
photographs taken before and at day 28. Right: Lissamine green staining scores (mean 6 SEM, 8 eyes). (E) Hematoxylin and eosin staining of the
cornea and the conjunctiva at day 28, representative of sections done on 2 eyes per group. S, stroma; CE, corneal endothelium. Scale bars: 100 lm
(cornea), 25 lm (conjunctiva).
FIGURE 6. Tissue levels following chronic CFTRact-K267 administration (3 nmol twice daily for 28 days). (A) Representative LC/MS elution curves
shown for CFTRact-K267 in indicated tissues. (B) CFTRact-K267 levels in ocular and extraocular tissues (mean 6 SEM, 8 rabbits). LC/MS detection
limit shown as vertical dashed line.
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the limit of detection in the aqueous and vitreous fluid and in
the blood and peripheral tissues. Ocular toxicity was not
observed as assessed by in vivo examination of the ocular
surface, cornea, and lens, by measurements of intraocular
pressure and corneal thickness, and by ocular histology.
Together these finding support the development of CFTRact-
K267 for dry eye disorders.
The potential difference measurement method used here,
which was developed initially for studies of ion channels at the
mouse ocular surface,8,21 was motivated by nasal potential
difference measurements used for decades to study CFTR
function in cystic fibrosis.22 Unlike short-circuit current
measurements in isolated cornea or conjunctiva,18,23 ocular
surface PD measurements provide information about CFTR
function in its native environment in which ocular surface
anatomy and physiology are preserved, which is important
because of heterogeneity in transport properties of the cornea
and conjunctiva21,24–26 and because of possible changes in
basal cyclic nucleotide levels following tissue excision. The PD
results here in rabbits showed rapid CFTR activation at the
ocular surface with maximal effects within a few minutes after
exposure to CFTRact-K267. Because of its simplicity and good
signal to noise, measurements of ocular surface PD may be
translatable to humans as a surrogate functional assay of drug
candidates targeting ion channels.
The PD results showed that amiloride produced a depolar-
ization averaging ~5 mV, much smaller than the total
hyperpolarization of >20 mV. Albeit a small depolarization,
this finding implicates the presence of an amiloride-sensitive
epithelial sodium channel, presumably ENaC, somewhere on
the ocular surface. However, no amiloride effect was seen in
short-circuit measurements on isolated conjunctiva, which
might be the consequence of the particular area of conjunctiva
studies or the limited sensitivity of the method. Prior studies on
sodium channels at the rabbit ocular surface, largely in the
older literature, reported mixed findings. Evidence for an
amiloride-insensitive sodium pathway was reported in rabbit
cornea26,27 and conjunctiva.28,29 Other studies, however, have
reported some amiloride-sensitive ENaC activity at the rabbit
ocular surface in vivo.30,31 It will be important to establish the
presence and magnitude of amiloride-inhibitable ENaC activity
at the human ocular surface for consideration of ENaC inhibitor
therapy for dry eye.
The substantial and sustained CFTR activation at the ocular
surface produced by CFTRact-K267, without tachyphylaxis, is
consistent with the known biology of CFTR as studied
extensively in the airways and intestine.10,32,33 An alternative
pro-secretory strategy for dry eye is pharmacological activation
of calcium-activated chloride channels, which are thought to
be expressed on conjunctival epithelia, mucin cells, and
lacrimal glands.23,34 The UTP analog diquafosol, which
activates epithelial P2Y2 receptors and downstream calcium
signaling, has been approved for dry eye in Japan, but did not
show efficacy in phase III trials in the United States,35 perhaps
because of the only transient calcium elevation and conse-
quent chloride channel activation produced by P2Y2 agonists.
Another pro-secretory strategy for increasing tear fluid is
anti-absorptive therapy by inhibition of ENaC sodium channels.
In a phase I/IIa study, the ENaC inhibitor P321 has shown
tolerability and safety in patients with mild to moderate dry eye
(Boyer JL, et al. IOVS 2016;57:ARVO E-Abstract 2875), and a
phase II study is in progress. Theoretical modeling supports
the efficacy of an anti-absorptive approach to increase tear
fluid, albeit with lower efficacy than a pro-secretory approach;
modeling also supports the additive action of anti-absorptive
and pro-secretory drugs.21 We note that pro-secretory or anti-
absorption drugs are combinable with anti-inflammatory drugs
because they target distinct mechanisms in dry eye pathogen-
esis. Finally, we note that pro-secretory or anti-absorptive
therapy may not correct lipid or mucin deficiency in some
cases of dry eye; however, augmentation of aqueous volume is
predicted to correct tear fluid hyperosmolality and down-
stream inflammation even in evaporative dry eye.
Although the results here support the development of
CFTRact-K267 for testing in human dry eye, several limitations
are noted. Optimization of the ocular formulation to deliver
CFTRact-K267 is needed, as the studies here used an original
formation established previously17 that contained DMSO to
ensure compound solubility. Moreover, longer term and
systemic toxicity studies, plus evaluation in additional species,
may be needed for further preclinical development. In addition
to STT measurement for tear production, other measures of
efficacy might include tear break-up time and tear fluid
osmolality. Finally, although rabbit eyes are more similar to
human than to rodent eyes, they may differ from human eyes
in their capacity to produce lacrimal fluid, in their corneal
epithelial thickness, and in their tolerability to ocular irritation,
and it is not known whether the rabbit nictitating membrane
contains conjunctival epithelium expressing CFTR that may
contribute to ocular fluid secretion.36
CONCLUSIONS
In summary, a small molecule CFTR activator with nanomolar
potency was effective in producing sustained tear fluid
hypersecretion in rabbits following single-dose topical admin-
istration. At therapeutic doses administered twice daily for 28
days, compound activity was not diminished, no signs of ocular
toxicity were observed, and the compound was not detectable
outside of the eye. CFTRact-K267 may thus be a safe and
effective therapy for human dry eye disorders alone or when
combined with other dry eye medications.
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